Titan Pharmaceuticals (NASDAQ:TTNP) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note released on Wednesday. The firm issued a sell rating on the specialty pharmaceutical company’s stock. Titan Pharmaceuticals Price Performance Shares of TTNP opened at $0.34 on Wednesday. Titan Pharmaceuticals has a 52-week low of $0.31 and a 52-week high […]

Leave a Reply

Your email address will not be published.

Previous post Rockwell Medical (NASDAQ:RMTI) Receives Buy Rating from HC Wainwright
Next post Russia shrugging off sanctions – Bloomberg